表紙
市場調查報告書

寡核苷酸合成的全球市場:產業趨勢、預測

Global Oligonucleotide Synthesis Market: Industry Trends and Forecast to 2026

出版商 Data Bridge Market Research Private Limited 商品編碼 910503
出版日期 內容資訊 英文 278 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
寡核苷酸合成的全球市場:產業趨勢、預測 Global Oligonucleotide Synthesis Market: Industry Trends and Forecast to 2026
出版日期: 2019年08月01日內容資訊: 英文 278 Pages
簡介

本報告提供全球寡核苷酸合成市場相關調查分析,市場概要,市場趨勢,各市場區隔的市場分析,各地區預測,主要企業等相關的系統性資訊。

第1章 簡介

第2章 市場區隔

第3章 市場概要

  • 促進因素
  • 阻礙因素
  • 機會
  • 新產品的開發、革新
  • 課題

第4章 摘要整理

第5章 重要考察

第6章 全球寡核苷酸合成市場:各產品類型

  • 概要
  • DNA寡核苷酸
  • RNA寡核苷酸

第7章 全球寡核苷酸合成市場:各類型

  • 概要
  • 寡核苷酸為基礎的醫藥品
  • 底層塗料
  • 探針
  • 中規模的合成Oligo
  • 大規模的合成Oligo
  • 連接試劑、配接器
  • 陣列為基礎的Oligo

第8章 全球寡核苷酸合成市場:各消耗品

  • 概要
  • 設備
  • 套件、試劑
  • 其他

第9章 全球寡核苷酸合成市場:各服務形式

  • 概要
  • 自訂
  • 事前指定
  • Oligo合成

第10章 全球寡核苷酸合成市場:各用途

  • 概要
  • 研究用
  • 治療用
  • 診斷用
  • 其他

第11章 全球寡核苷酸合成市場:各終端用戶

  • 概要
  • 生物製藥、生物科技
  • 學術研究機關
  • CRO
  • 醫院
  • 其他

第12章 全球寡核苷酸合成市場:各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第13章 全球寡核苷酸合成市場:企業形勢

  • 企業佔有率分析:世界
  • 企業佔有率分析:北美
  • 企業佔有率分析:歐洲
  • 企業佔有率分析:亞太地區

第14章 SWOT分析

第15章 企業簡介

  • DANAHER
  • MERCK KGAA
  • GENERAL ELECTRIC
  • THERMO FISHER SCIENTIFIC INC.
  • AGILENT TECHNOLOGIES, INC.
  • EUROFINS SCIENTIFIC
  • ATDBIO LTD.
  • Ajinomoto
  • BIANOSCIENCE GMBH
  • BIO BASIC INC
  • BIOLYTIC LAB PERFORMANCE INC.
  • BIO-SYNTHESIS INC
  • GENSCRIPT
  • KANEKA EUROGENTEC S.A.
  • LGC LIMITED
  • 日東電工
  • POLYGEN GMBH
  • QIAGEN
  • QUINTARA BIOSCIENCES
  • TRILINK BIOTECHNOLOGIES, LLC
  • TWIST BIOSCIENCE

第16章 結論

第17章 問卷調查

第18章 相關調查

目錄

Global oligonucleotides synthesis market is projected to register a substantial CAGR of 9.3% in the forecast period 2019 to 2026. The new market report contains data for historic years 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation

By Product Type (DNA Oligonucleotides, RNA Oligonucleotides), Type (Oligonucleotide-Based Drugs, Primers, Probes, Intermediate-Scale Synthesized Oligos, Large-Scale Synthesized Oligos, Linkers & Adaptors, Array-Based Oligos), Consumables (Instruments, Kits & Reagents, Others), Service Type (Custom Oligos, Predesigned Oligos, Oligo Synthesis), Application (Research Applications, Therapeutic Applications, Diagnostic Applications, Others), End User (Biopharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations, Hospitals, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East & Africa)

Some of the major factors contributing to the growth of global oligonucleotides synthesis market:

  • Rise in venture investments
  • Increasing government investments, R&D expenditure in pharmaceutical and biotechnology companies

Market Players

The key market players for global oligonucleotides synthesis market are listed below:

  • Agilent Technologies, Inc.
  • Atdbio Ltd.
  • LGC Limited
  • Bio-Synthesis Inc.
  • Eurofins Genomics
  • Kaneka Eurogentec S.A.
  • General Electric
  • Genscript
  • AJINOMOTO CO., INC (Genedesign, Inc.)
  • Danaher
  • Merck KgaA
  • Lgc Biosearch Technologies
  • Nitto Denko
  • Thermo Fisher Scientific
  • Trilink Biotechnologies, Llc
  • Biolytic Lab Performance Inc.
  • Polygen Gmbh
  • Quintara Biosciences
  • Bio Basic Inc.
  • Danaher (Integrated DNA Technologies, Inc)
  • Twist Bioscience
  • Others

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7 DBMR MARKET POSITION GRID
  • 2.8 DBMR VENDOR SHARE ANALYSIS
  • 2.9 MULTIVARIATE MODELING
  • 2.10 PRODUCTS LIFELINE CURVE
  • 2.11 SECONDARY SOURCES
  • 2.12 ASSUMPTIONS

3 MARKET OVERVIEW

  • 3.1 DRIVERS
    • 3.1.1 INCREASING USAGE OF SYNTHESIZED OLIGOS IN MOLECULAR DIAGNOSTICS AND CLINICAL APPLICATIONS
    • 3.1.2 INCREASING GOVERNMENT INVESTMENTS, R&D EXPENDITURE IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 3.2 GENETIC DISORDERS
  • 3.3 RESTRAINTS
    • 3.3.1 LACK OF SKILLED PROFESSIONALS
    • 3.3.2 INCREASING IN-HOUSE PRODUCTION HINDERING THE GLOBAL MARKET GROWTH
  • 3.4 OPPORTUNITIES
    • 3.4.1 STRATEGIC INITIATIVES OF THE MARKET PLAYERS
  • 3.5 DEVELOPMENTS AND INNOVATIONS OF NEW PRODUCTS
  • 3.6 CHALLENGES
    • 3.6.1 STRINGENT REGULATIONS
    • 3.6.2 DRUG DELIVERY & TOXICOLOGY CHALLENGES

4 EXECUTIVE SUMMARY

  • 4.1 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: SEGMENTATION
  • 4.2 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE INCREASING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2019 TO 2026

5 PREMIUM INSIGHTS

  • 5.1 ASIA-PACIFIC IS THE MAXIMUM GROWING AND NORTH AMERICA IS THE MOST PROFITABLE REVENUE POCKETS FOR GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET IN THE FORECAST PERIOD OF 2019 TO 2026

6 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT TYPE

  • 6.1 OVERVIEW
  • 6.2 DNA OLIGONUCLEOTIDES
  • 6.3 RNA OLIGONUCLEOTIDES

7 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY TYPE

  • 7.1 OVERVIEW
  • 7.2 OLIGONUCLEOTIDE-BASED DRUGS
  • 7.3 PRIMERS
  • 7.4 PROBES
  • 7.5 INTERMEDIATE-SCALE SYNTHESIZED OLIGOS
  • 7.6 LARGE-SCALE SYNTHESIZED OLIGOS
  • 7.7 LINKERS & ADAPTORS
  • 7.8 ARRAY-BASED OLIGOS

8 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY CONSUMABLES

  • 8.1 OVERVIEW
  • 8.2 INSTRUMENTS
  • 8.3 KITS & REAGENTS
  • 8.4 OTHERS

9 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY SERVICE TYPE

  • 9.1 OVERVIEW
  • 9.2 CUSTOM OLIGOS
    • 9.2.1 MODIFICATION
    • 9.2.2 PURIFICATION
  • 9.3 PREDESIGNED OLIGOS
  • 9.4 OLIGO SYNTHESIS
    • 9.4.1 1000 NMOL
    • 9.4.2 5,000 NMOL
    • 9.4.3 100-200 NMOL
    • 9.4.4 25-50 NMOL
    • 9.4.5 10,000 NMOL
    • 9.4.6 MORE THAN 10,000 NMOL

10 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION

  • 10.1 OVERVIEW
  • 10.2 RESEARCH APPLICATIONS
    • 10.2.1 PCR
    • 10.2.2 QPCR
    • 10.2.3 SEQUENCING
    • 10.2.4 GENE SYNTHESIS
    • 10.2.5 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
    • 10.2.6 DNA MICROARRAYS
    • 10.2.7 OTHER APPLICATIONS
  • 10.3 THERAPEUTIC APPLICATIONS
    • 10.3.1 DNA & ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES
    • 10.3.2 RNAI OLIGONUCLEOTIDE-BASED THERAPIES
    • 10.3.3 CPG OLIGONUCLEOTIDE-BASED THERAPIES
    • 10.3.4 OTHERS
  • 10.4 DIAGNOSTIC APPLICATIONS
  • 10.5 OTHERS

11 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER

  • 11.1 OVERVIEW
  • 11.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.3 ACADEMIC & RESEARCH INSTITUTES
  • 11.4 CONTRACT RESEARCH ORGANIZATIONS
  • 11.5 HOSPITALS
  • 11.6 OTHERS

12 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY GEOGRAPHY

  • 12.1 OVERVIEW
  • 12.2 NORTH AMERICA
    • 12.2.1 U.S.
    • 12.2.2 CANADA
    • 12.2.3 MEXICO

  • 12.3 EUROPE
    • 12.3.1 GERMANY
    • 12.3.2 U.K.
    • 12.3.3 FRANCE
    • 12.3.4 SWITZERLAND
    • 12.3.5 ITALY
    • 12.3.6 BELGIUM
    • 12.3.7 DENMARK
    • 12.3.8 SWEDEN
    • 12.3.9 SPAIN
    • 12.3.10 NETHERLANDS
    • 12.3.11 RUSSIA
    • 12.3.12 TURKEY
    • 12.3.13 REST OF EUROPE
  • 12.4 ASIA-PACIFIC
    • 12.4.1 CHINA
    • 12.4.2 JAPAN
    • 12.4.3 SOUTH KOREA
    • 12.4.4 INDIA
    • 12.4.5 AUSTRALIA
    • 12.4.6 SINGAPORE
    • 12.4.7 MALAYSIA
    • 12.4.8 THAILAND
    • 12.4.9 INDONESIA
    • 12.4.10 PHILIPPINES
    • 12.4.11 REST OF ASIA-PACIFIC
  • 12.5 SOUTH AMERICA
    • 12.5.1 BRAZIL
    • 12.5.2 REST OF SOUTH AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 SOUTH AFRICA
    • 12.6.2 ISRAEL
    • 12.6.3 REST OF MIDDLE EAST & AFRICA

13 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY LANDSCAPE

  • 13.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 13.3 COMPANY SHARE ANALYSIS: EUROPE
  • 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

14 SWOT & DBMR ANALYSIS

15 COMPANY PROFILE

  • 15.1 DANAHER
    • 15.1.1 COMPANY SNAPSHOT
    • 15.1.2 REVENEUE ANALYSIS
    • 15.1.3 COMPANY SHARE ANALYSIS
    • 15.1.4 PRODUCT PORTFOLIO
    • 15.1.5 RECENT DEVELOPMENTS
  • 15.2 MERCK KGAA
    • 15.2.1 COMPANY SNAPSHOT
    • 15.2.2 REVENUE ANALYSIS
    • 15.2.3 COMPANY SHARE ANALYSIS
    • 15.2.4 SERVICE PORTFOLIO
    • 15.2.5 PRODUCT PORTFOLIO
    • 15.2.6 RECENT DEVELOPMENT
  • 15.3 GENERAL ELECTRIC
    • 15.3.1 COMPANY SNAPSHOT
    • 15.3.2 REVENEUE ANALYSIS
    • 15.3.3 COMPANY SHARE ANALYSIS
    • 15.3.4 PRODUCT PORTFOLIO
    • 15.3.5 RECENT DEVELOPMENTS
  • 15.4 THERMO FISHER SCIENTIFIC INC.
    • 15.4.1 COMPANY SNAPSHOT
    • 15.4.2 REVENUE ANALYSIS
    • 15.4.3 COMPANY SHARE ANALYSIS
    • 15.4.4 SERVICE PORTFOLIO
    • 15.4.5 PRODUCT PORTFOLIO
    • 15.4.6 RECENT DEVELOPMENTS
  • 15.5 AGILENT TECHNOLOGIES, INC.
    • 15.5.1 COMPANY SNAPSHOT
    • 15.5.2 REVENUE ANALYSIS
    • 15.5.3 COMPANY SHARE ANALYSIS
    • 15.5.4 PRODUCT PORTFOLIO
    • 15.5.5 RECENT DEVELOPMENTS
  • 15.6 EUROFINS SCIENTIFIC
    • 15.6.1 COMPANY SNAPSHOT
    • 15.6.2 REVENUE ANALYSIS
    • 15.6.3 COMPANY SHARE ANALYSIS
    • 15.6.4 SERVICE PORTFOLIO
    • 15.6.5 RECENT DEVELOPMENTS
  • 15.7 ATDBIO LTD.
    • 15.7.1 COMPANY SNAPSHOT
    • 15.7.2 PRODUCT PORTFOLIO
    • 15.7.3 SERVICE PORTFOLIO
    • 15.7.4 RECENT DEVELOPMENT
  • 15.8 AJINOMOTO CO.,INC.
    • 15.8.1 COMPANY SNAPSHOT
    • 15.8.2 REVENUE ANALYSIS
    • 15.8.3 PRODUCT PORTFOLIO
    • 15.8.4 RECENT DEVELOPMENT
  • 15.9 BIANOSCIENCE GMBH
    • 15.9.1 COMPANY SNAPSHOT
    • 15.9.2 PRODUCT PORTFOLIO
    • 15.9.3 RECENT DEVELOPMENT
  • 15.10 BIO BASIC INC
    • 15.10.1 COMPANY SNAPSHOT
    • 15.10.2 SERVICE PORTFOLIO
    • 15.10.3 RECENT DEVELOPMENT
  • 15.11 BIOLYTIC LAB PERFORMANCE INC.
    • 15.11.1 COMPANY SNAPSHOT
    • 15.11.2 PRODUCT PORTFOLIO
    • 15.11.3 RECENT DEVELOPMENTS
  • 15.12 BIO-SYNTHESIS INC
    • 15.12.1 COMPANY SNAPSHOT
    • 15.12.2 SERVICE PORTFOLIO
    • 15.12.3 RECENT DEVELOPMENT
  • 15.13 GENSCRIPT
    • 15.13.1 COMPANY SNAPSHOT
    • 15.13.2 REVENEUE ANALYSIS
    • 15.13.3 PRODUCT PORTFOLIO
    • 15.13.4 RECENT DEVELOPMENTS
  • 15.14 KANEKA EUROGENTEC S.A.
    • 15.14.1 COMPANY SNAPSHOT
    • 15.14.2 PRODUCT PORTFOLIO
    • 15.14.3 SERVICE PORTFOLIO
    • 15.14.4 RECENT DEVELOPMENTS
  • 15.15 LGC LIMITED
    • 15.15.1 COMPANY SNAPSHOT
    • 15.15.2 SERVICE PORTFOLIO
    • 15.15.3 PRODUCT PORTFOLIO
    • 15.15.4 RECENT DEVELOPMENTS
  • 15.16 NITTO DENKO CORPORATION
    • 15.16.1 COMPANY SNAPSHOT
    • 15.16.2 REVENUE ANALYSIS
    • 15.16.3 SERVICE PORTFOLIO
    • 15.16.4 RECENT DEVELOPMENTS
  • 15.17 POLYGEN GMBH
    • 15.17.1 COMPANY SNAPSHOT
    • 15.17.2 PRODUCT PORTFOLIO
    • 15.17.3 RECENT DEVELOPMENT
  • 15.18 QIAGEN
    • 15.18.1 COMPANY SNAPSHOT
    • 15.18.2 REVENUE ANALYSIS
    • 15.18.3 PRODUCT PORTFOLIO
    • 15.18.4 RECENT DEVELOPMENTS
  • 15.19 QUINTARA BIOSCIENCES
    • 15.19.1 COMPANY SNAPSHOT
    • 15.19.2 PRODUCT PORTFOLIO
    • 15.19.3 RECENT DEVELOPMENT
  • 15.20 TRILINK BIOTECHNOLOGIES, LLC
    • 15.20.1 COMPANY SNAPSHOT
    • 15.20.2 PRODUCT PORTFOLIO
    • 15.20.3 RECENT DEVELOPMENTS
  • 15.21 TWIST BIOSCIENCE
    • 15.21.1 COMPANY SNAPSHOT
    • 15.21.2 REVENEUE ANALYSIS
    • 15.21.3 PRODUCT PORTFOLIO
    • 15.21.4 RECENT DEVELOPMENTS

16 CONCLUSION

17 QUESTIONNAIRE

18 RELATED REPORTS

LIST OF FIGURES

  • FIGURE 1 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET
  • FIGURE 2 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: DATA VALIDATION MODEL
  • FIGURE 3 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: DROC ANALYSIS
  • FIGURE 4 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: GLOBAL VS REGIONAL
  • FIGURE 5 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL OLIGONUCLEOTIDE SYSNTHESIS MARKET
  • FIGURE 9 INCREASING USAGE OF SYNTHESIZED OLIGOS IN MOLECULAR DIAGNOSTICS AND CLINICAL APPLICATIONS AND INCREASING GOVERNMENT INVESTMENTS, R&D EXPENDITURE IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES AND RISE IN VENTURE INVESTMENTS ARE EXPECTED TO DRIVE THE GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET IN THE FORECAST PERIOD OF 2019 TO 2026
  • FIGURE 10 DNA OLIGONUCLEOTIDES IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET IN THE FORECAST PERIOD OF 2019 TO 2026
  • FIGURE 11 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: BY PRODUCT TYPE, 2018
  • FIGURE 12 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: BY TYPE, 2018
  • FIGURE 13 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: BY CONSUMABLES, 2018
  • FIGURE 14 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: BY SERVICE TYPE, 2018
  • FIGURE 15 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: BY APPLICATION, 2018
  • FIGURE 16 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: BY END USER, 2018
  • FIGURE 17 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: SNAPSHOT (2018)
  • FIGURE 18 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: BY GEOGRAPHY (2018)
  • FIGURE 19 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: BY GEOGRAPHY (2019 & 2026)
  • FIGURE 20 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: BY GEOGRAPHY (2018 & 2026)
  • FIGURE 21 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: BY PRODUCT TYPE (2019-2026)
  • FIGURE 22 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET: SNAPSHOT (2018)
  • FIGURE 23 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET: BY COUNTRY (2018)
  • FIGURE 24 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 25 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY (2018 & 2026)
  • FIGURE 26 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT TYPE (2018 - 2026)
  • FIGURE 27 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET: SNAPSHOT (2018)
  • FIGURE 28 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET: BY COUNTRY (2018)
  • FIGURE 29 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 30 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY (2018 & 2026)
  • FIGURE 31 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT TYPE (2018 - 2026)
  • FIGURE 32 ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET: SNAPSHOT (2018)
  • FIGURE 33 ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET: BY COUNTRY (2018)
  • FIGURE 34 ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 35 ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY (2018 & 2026)
  • FIGURE 36 ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, PRODUCT TYPE (2018 - 2026)
  • FIGURE 37 SOUTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET: SNAPSHOT (2018)
  • FIGURE 38 SOUTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET: BY COUNTRY (2018)
  • FIGURE 39 SOUTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 40 SOUTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY (2018 & 2026)
  • FIGURE 41 SOUTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT TYPE (2018 - 2026)
  • FIGURE 42 MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET: SNAPSHOT (2018)
  • FIGURE 43 MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET: BY COUNTRY (2018)
  • FIGURE 44 MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 45 MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY (2018 & 2026)
  • FIGURE 46 MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET, PRODUCT TYPE (2018 - 2026)
  • FIGURE 47 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 48 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 49 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 50 ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY SHARE 2018 (%)
Back to Top